Latest News

Dow Jones Newswires: Novartis hemoglobinuria trial meets two primary endpoints


Novartis AG


said Monday that a study on a drug to treat adult paroxysmal nocturnal hemoglobinuria, a red blood cell condition, has met its two primary endpoints.

The trial studied a drug named Iptacopan and established its superiority to a previously used treatment in helping patients with debilitating anemia who would normally undergo blood transfusions, according to the company.

“Iptacopan was well tolerated with a favorable safety profile consistent with previously reported data,” Novartis said.

Write to Cecilia Butini at

Dow Jones Newswires: Royal Philips swings to wider-than-forecast net loss of $1.31 billion

Previous article

Dow Jones Newswires: Galp swings to profit, cuts guidance

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News